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One focus of AChE research lies in the development of new drugs that could prevent and ⁄ or treat poisoning from organophosphates (OPs), toxic agents commonly used in insecticides as well as in chemical warfare agents (2) . OP poisoning causes the inactivation of AChE that prevents synaptic transmission, leading to muscle paralysis, hypertension, and malfunction of various organ systems, ultimately leading to death.
Two ligand-binding sites in AChE have been identified, the acylation site (A-site) at the base of a deep active-site gorge and the peripheral site (P-site) near the gorge entrance through which ligands must pass on their way to the A-site (3) (4) (5) . Figure 1 shows the binding gorge of human AChE with acetylcholine modeled into both the Asite (green) and P-site (pink) as described in Methods. OPs are toxic because they covalently react with S203 in the A-site. Wilson and Ginsburg (6,7) conceived complementary oxime compounds that could re-activate OP-poisoned AChE. These drugs serve as defenses against OP toxicity, but they work only on OP-inactivated AChE. It would be beneficial to develop prophylactic drugs that prevent AChE from interacting with OPs in the first place, and our objective is to design drug-like compounds to serve this function. One strategy is to obtain small molecules that bind at or near the AChE P-site. Such molecules could be modified, in principle, to sterically discriminate access to the A-site in a way that still allows entry of acetylcholine but limits the entrance of the larger OPs. This is a challenging task. While a competitive inhibitor that binds to the A-site would reduce the irreversible OP inactivation rate, it would equally reduce the rate of acetylcholine hydrolysis and provide no benefit. The binding of a ligand X to the AChE P-site is known to decrease the association and dissociation rate constants for the binding of a ligand Y to the A-site by factors of up to 400 (5, 8) , and it is this feature that we propose to exploit in designing a P-site ligand that would selectively block OP association with the A-site. Such a ligand would need very high affinity (pM) for the P-site to effectively block OP inactivation, and a strategy designed to evolve a series of lead compounds with progressively higher affinity is necessary. Here we report on our first steps in such an evolution.
The development of structure-activity relationships for ligands that bind specifically to the AChE P-site is in its infancy. Because of a possible AChE P-site role in promoting amyloid-b aggregation in Alzheimer's disease (9) , in silico screening of a limited 270-member library of compounds was initiated to identify new ligands with P-site specificity (10, 11) . Several identified compounds as well as tetrahydrocannabinol (9) were shown experimentally to bind to the P-site.
We used a virtual screening approach to identify P-site ligands from a much larger library of compounds. To establish the ligand docking procedures used to screen the library, we selected several compounds known to bind to either the A-site or the P-site by X-ray crystallography. These were first redocked back into their original crystal structures with two docking programs, AutoDock Vina (12) and AUTODOCK version 4.2 (13) . These compounds were then docked into human AChE to confirm that the docking programs could identify a preference for the correct site. Finally, virtual screening was used to identify compounds that bind preferentially to the P-site, and still allow acetylcholine to bind to the A-site of AChE. The NCI Diversity Set II (14) was first docked using Vina in combination with a consensus scoring approach, and after an initial round of testing, was docked using AUTODOCK 4.2. Candidate compounds predicted to show selective P-site binding were obtained from the NCI and tested experimentally with an AChE inhibitor-competition assay that can distinguish between inhibitor binding to the A-site or P-site.
Methods

Preparation of crystal structures
The structure of human acetylcholinesterase (AChE) was derived from the crystal structure of the AChE complexed with fasciculin-II deposited in the RCSB Protein Databank (15) (PDB id:1B41) by Kryger and co-workers (16); only the AChE was retained for our modeling studies. The locations of the A-and P-sites were defined from the crystal structure of the S203A mutant of mouse AChE complexed with acetylcholine (17) (PDB id: 2HA4), which shows one molecule of acetylcholine in each site. The 1B41 and 2HA4 structures were superimposed, and the acetylcholine molecules from 2HA4 were merged with AChE from 1B41. This formed our model of human AChE complexed with acetylcholine used in subsequent studies.
Docking controls
Crystal structures of several additional AChE-ligand complexes have been deposited in the PDB, including complexes at the A-site with edrophonium (18) (2ACK) or tacrine (19) (1ACJ) and complexes at the P-site with thioflavin T (20) (2J3Q), decidium (21) (1J07), propidium (21) (1N5R), methylene blue (22) (2W9I), or aflatoxin B1(23) (2XI4). Crystal structures of AChE complexes involving ligands that span both sites also have been obtained, but these ligands are not of interest in this study and were not examined. These structures all were obtained as complexes with Torpedo californica AChE (TcAChE) or Mus musculus (MmAChE). The complexes were superimposed with our human model of AChE, and therefore, all coordinates are in relation to 1B41, with the A-site and P-site defined by the acetylcholines originally from 2HA4. These ligands, shown in Figure 2 , were used to test our docking procedures. In each case, the ligand was removed from the original structure and redocked into that structure with a docking box centered on the original ligand position and measuring 25.2 on each side, sufficiently large to encompass the ligands in this study. For the redocking controls, all crystal waters were retained.
Ability to reproduce crystal structure binding mode was assessed by molecular volume overlap, presented as a percentage of the volume of the X-ray ligand. For these calculations, we used ROCS (OpenEye Scientific Software, Sante Fe, NM, USA) to determine the absolute volume and divided the volume overlap of a ligand with itself to determine percentages. Overlap close to 100% can be interpreted as correct prediction of binding mode, while mid-range overlaps typically bind in the correct site with an incorrect conformation, and low values indicate binding in a different site.
Additionally, each of these ligands was docked into our model of human AChE under three different conditions: apo-AChE, with both the A-and P-sites free; AChE with the acetylcholine bound in the Figure 1 : The AChE catalytic site is a narrow active-site gorge some 20 deep (yellow) that penetrates nearly to the center of the $65 kDa catalytic subunits. Near the base of the gorge is the A-site where H447, E334, and S203 (red) participate in a triad that catalyzes the transient acylation and deacylation of S203 during each substrate turnover. The P-site is spanned by residues W286 near the mouth of the gorge and D74 near a constriction at the boundary between the P-site and the A-site. (B) Acetylcholine modeled into the A-site (green) and P-site (pink) as described in Methods.
A-site; and AChE with acetylcholine bound at both the A-site and P-site. This docking was intended to demonstrate the ability of the docking procedure to correctly produce the known binding site of each ligand. The docking was performed with both Vina and AUTO-DOCK 4.2 using a docking box located at the center of mass of the two modeled acetylcholines (119.1, 109.1, )133.1), measuring 51.2 on each side, more than large enough to encompass both sites. In this case, the overlap volume was calculated as overlap with the A-and P-site modeled acetylcholines.
Virtual screening
Virtual screening of the NCI Diversity Set II (14) , which consists of 1364 diverse compounds selected from the full library of 140 000 compounds, was docked to identify candidate drug-like compounds that might complementarily bind at or near the P-site of human AChE. Three sets of dockings were performed: apo-AChE, with both the A-and P-site free; AChE with the acetylcholine bound in the Asite; and AChE, with acetylcholine bound at both the A-and P-sites. These conditions were selected to distinguish compounds that have a preference for each specific site, as well as those that bind outside either site. Again, the docking box was centered at the center of mass of the two acetylcholine molecules and measured 51.2 on each side to allow docking to any site. For each compound in each of the different docking protocols, the 20 top-scoring poses of the complexes were retained. The docking simulations were performed on the IBM cluster at the Washington University High-Performance Computing Center in Saint Louis.
A total of 27 280 poses (20 top-scoring poses for 1364 compounds) obtained from each of the docking protocols were re-ranked using a consensus scoring approach (24-26) that has been successful in virtual screening of other targets (27, 28) . This technique should eliminate any particular bias and increase confidence in the ranking of binding affinities and ⁄ or docking scores used as criteria to select compounds for experimental testing. In this case, we used the Vina score, X-Score (29) , and CSCORE (30) . Compounds were selected that had poses ranked in the top 1500 with all three scoring routines. These compounds were limited to £10 rotatable bonds, and filtered by Lipinski's 'Rule of 5': MW < 500, logP < 5, h-bond acceptors < 10, h-bond donors < 5; to help insure bioavailability (31) , and selected compounds were examined in enzymatic assays with AChE.
The dockings of all 1364 NCI compounds were also conducted with AUTODOCK version 4.2, with or without acetylcholine bound to the A-site alone or to both the A-and P-sites. Parameters used for the dockings were defaults except for the following: npts of 256 in each dimension, grid spacing of 0.200, ls_search_freq of 0.2, ga_run of 20, ga_num_evals of 10 000 000. The center of the two acetylcholine molecules was set as the grid center for docking, with a docking box 51.2 on each side.
Inhibition of AChE hydrolysis of acetylthiocholine at low substrate concentrations Recombinant human AChE was expressed as a secreted, disulfidelinked dimer in Drosophila S2 cells and purified as outlined previously (32) . Recrystallized methylene blue was a gift of Dr. Lev Weiner and Dr Esther Roth at the Weizmann Institute in Rehovath, Israel, and concentrations were assigned by absorbance at 663 nm with e663 nm = 74 000 M )1 cm )1 . Thioflavin T and edrophonium were 
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Chem Biol Drug Des 2011; 78: 495-504prepared as described previously (33) . Substrate hydrolysis rates v were measured with acetylthiocholine and 5,5¢-dithiobis-(2-nitrobenzoic acid) (DTNB, 0.33 mM) in a coupled Ellman reaction in assay buffer (20 mM sodium phosphate buffer (pH 7.0) and 0.02% Triton X-100 unless otherwise noted) at 25°C (34).
The assay used here to assess inhibition of AChE activity measures the second-order hydrolysis rate constant k E obtained when the substrate concentration [S] is much less than the Michaelis constant K app (34) . Under these conditions, Scheme 1 includes all relevant enzyme species. This scheme assumes that substrate binds initially to the P-site (E S P ) before progressing to the A-site (ES) where it is hydrolyzed to products P, and it can be applied both to inhibitors that bind at the A-site (L P = I, and 1 ⁄ i = 0) and to inhibitors that bind at the P-site (L P = I P ) with dissociation constants K I . Under these second-order conditions, substrate hydrolysis rates
where [E] tot is the total enzyme concentration, and k E is measured from eqn 1 (35) .
In eqn 1, z = k E [E] tot and t is the time after mixing E and S. Because acetylthiocholine is hydrolyzed by AChE at nearly diffusioncontrolled rates, inhibitor binding to either the A-or P-sites results in an expression for the ratio of k E in the absence of inhibitor (k E[I] = 0 ) to k E in the presence of inhibitor (k E + I ) given by eqn 2 (34).
If a series of assays are conducted with a fixed concentration of one inhibitor I1 together with varying concentrations of a second inhibitor I2, k E in the presence of both inhibitors (here denoted k E + I2 ) relative to k E when only I1 is present (here denoted k E[I2] = 0 ) is given by eqn 3 (33).
In this equation, K 1 , K 2 , and K 12 are the equilibrium dissociation constants for I1 with E, I2 with E, and I1 with the EAEI2 complex, respectively. The value of [I1] ⁄ K 12 will be significantly >0 only if the ternary complex EAEI1AEI2 can form, and this analysis, thus, can be used to detect ternary complex formation.
Assay of NCI diversity set compounds
Compounds were dissolved in dimethyl sulfoxide (DMSO) at 10-50 mM and diluted (1:100) into assay buffer. If the compound was insoluble after dilution, the DMSO stock was diluted (1:10) into methanol and then diluted further (1:10) into assay buffer. The assay solvent for the control without a compound was matched to that with compound. AChE activity was essentially unaffected by 10% methanol but was inhibited about 2-fold in the presence of 1% DMSO. However, inclusion of 10% methanol decreased the reproducibility of k E .
Results and Discussion
Docking controls
The AChE binding sites of the compounds presented in Figure 2 are known from X-ray crystallography, and for each, the compound was removed from the structure and redocked with Vina or AUTODOCK 4.2. The ability to reproduce the X-ray binding mode is presented as the percent overlap of the docked ligand with the X-ray binding mode in Table 1 . Docking with Vina was more successful at locating the ligand within the original binding site than AUTODOCK 4.2, as each docked ligand had a higher overlap with the X-ray structure. However, lack of complete overlap for most ligands describes at least a shift in position of the docked compounds, and some molecules, such as tacrine, are flipped within their correct site. The ligand ranking by docking energy agrees for the two programs except for propidium and decidium, likely due to the difficulty in docking these flexible molecules. For AUTODOCK 4.2, docking acetylcholine to 2HA4 with both copies of the crystallographic acetylcholine ligand removed results in consistent docking to only the A-site, even though both the A-and P-sites were available. Docking to AChE with the A-site occupied by the crystallographic acetylcholine results in the second acetylcholine docking reliably to the P-site.
S + E
Scheme 1: Enzyme species considered in kinetic model. Using Vina, acetylcholine is docked into both the A-site and P-site if they are unoccupied.
Crystal water molecules play an important role in accurately reproducing crystal structures in docking. This was noted specifically for AChE by Dickerson and co-workers (10), who observed that crystal waters greatly improved docking results for propidium and decidium. We observe this same behavior with several ligands, including acetylcholine and edrophonium shown in Figure 3 . Without crystal waters, ( Figure 3A ) edrophonium docks to the A-site, but only partially overlaps with the crystal structure binding mode (28.8% volume overlap). The inclusion of only five of the crystal structure waters ( Figure 3B ) in the A-and P-sites results in a docked structure that much more closely matches the crystal structure ligand (86.7% overlap).
As A-site waters in AChE are well-known, inclusion of explicit waters in docking would be preferred. However, given the diverse chemotypes in our compound database, it is not possible to know prior to docking which compounds may interact with or displace the water molecules. Therefore, as an additional control calculation, we docked these same known ligands to human AChE with all waters removed to assess the ability of Vina and AUTODOCK 4.2 to correctly predict the preferred binding site for each ligand under virtual screening conditions.
Docking with human AChE
The three-dimensional structures of TcAChE, MmAChE, and human AChE are very similar, and most features of the active-site gorge are conserved between the species. Nevertheless, to confirm that the results obtained with TcAChE and MmAChE also apply to human AChE, docking with Vina and AUTODOCK 4.2 to human AChE was repeated for all the ligands in Figure 2 . Docking trials were performed with three different conditions: apo-AChE, with both the A-and P-site free; AChE with the acetylcholine bound in the A-site; and AChE with acetylcholine bound at both the A-and P-site.
Docking energies for both Vina and AUTODOCK 4.2 are presented in Table 2 for the apo-AChE docking (no bound acetylcholine). Binding in the correct site is described by the percent overlap with acetylcholines in the A-site and P-site modeled into 1B41 through superposition of 2HA4. A measurable percent overlap indicates it is unlikely that the modeled acetylcholine and the docked ligand could bind simultaneously in the given binding mode. When only a partial overlap is observed, typically the ligand is docked immediately adjacent to the modeled acetylcholine.
All ligands are predicted to bind to the known preferred site except for tacrine docking by Vina, which was docked to the P-site. Decidium docked by Vina spans both sites, but is predominantly located in the P-site. Acetylcholine was docked by both programs into both the A-and P-sites, with a slight preference in predicted energy for the A-site, although none exactly reproduces the crystal structure binding mode. As with the redocking control, the ranking by docking energy agrees between Vina and AUTODOCK 4.2, with the exception of propidium and decidium.
The docking to human AChE with acetylcholine modeled into either the A-site or both the A-and P-sites produces similar results (data not shown). As each site is occupied, the docking algorithms will identify another binding location, but with less favorable energy. It A B Figure 3 : Docking of edrophonium into Torpedo apo-AChE using AUTODOCK 4.2 (A) with crystal waters removed; (B) with crystal waters retained. Crystal structure ligand and water in thin lines and docked results in thick lines. should be noted that the percent overlaps in Table 1 are with the crystallographic ligands themselves but in Table 2 are with modeled acetylcholine originally from the 2HA4 crystal structure. Therefore, these values are not directly comparable except for acetylcholine itself. We do observe a decrease in percent overlap for acetylcholine between the redocking (Table 1 ) and human docking (Table 2) , but this is expected because of the removal of crystal structure water from human AChE.
Overall, these docking controls suggest that both the Vina and AUTODOCK 4.2 programs may be useful for virtual screening for Psite binders of AChE. Vina more accurately predicted crystal structure binding modes, but AUTODOCK 4.2 was better at predicting the correct binding site. The exact orientations of some docked poses were not always reproduced, but this is not surprising considering the limitations in the scoring functions and search algorithms used in docking. To minimize some of these limitations, our Vina virtual screening protocol employed an established consensus scoring approach (27, 28) that incorporates X-Score and CSCORE with the predicted binding energy from docking.
Identifying the binding site
The inhibition of second-order, substrate-hydrolysis rates k E as measured with eqns 2 and 3 provides a convenient framework for experimentally examining the interaction of an inhibitor with free AChE. The assays are designed to assign the binding location of an unknown inhibitor by examining its competition with inhibitors whose binding sites are known from X-ray crystallography. The approach is illustrated in Figure 4 , where the A-site inhibitor edrophonium and the P-site inhibitor thioflavin T are employed as the known inhibitors and methylene blue is analyzed as the unknown inhibitor. The data in Figure 4A show that k E[I] = 0 ⁄ k E + I with all three inhibitors has a linear dependence on the inhibitor concentration [I], in accord with eqn 2. In this case, the simplified inhibitorcompetition analysis in eqn 3 can be applied (33, 34, 36) to determine whether the unknown inhibitor binds to the A-and ⁄ or P-sites. The analysis is designed to detect any ternary complex formed when the unknown inhibitor and the inhibitor with a known binding site are added to AChE simultaneously. The data with methylene blue alone are plotted in the reciprocal form k E + I ⁄ k E[I] = 0 in Figure 4B,C to emphasize K I as the IC 50 , or inhibitor concentration at which k E + I ⁄ k E[I] = 0 was decreased by 50%. When a fixed concentration of edrophonium was included in the assays, the IC 50 for methylene blue was shifted slightly to the right, indicating some competition between the two inhibitors. The affinity of methylene blue or edrophonium in the ternary complex decreased by a factor of 3.3 relative to their affinities in their respective binary complexes with the free enzyme, a small change that indicated slight steric overlap between the two binding sites. For comparison, the relative affinities of edrophonium and thioflavin T in the ternary complex with AChE were virtually identical to those in their respective binary complexes (34) , and thus, these two known standards show no overlap between their binding sites. In contrast, the IC 50 for methylene blue in Figure 4C was shifted well to the right by the addition of thioflavin T. One can calculate the extent of the shift that would result from complete competition and no ternary complex formation from the K I values of the inhibitors individually, and these calculated shifts are shown as the dotted lines in Figure 4B ,C. Methylene blue and thioflavin T essentially showed complete competition in Figure 4C . These data indicate that methylene blue binds to the AChE P-site in a fashion that is competitive with thioflavin T, but slightly overlaps edrophonium bound at the A-site. This interpretation is confirmed by the P-site binding of methylene blue complexed with AChE in the crystal structure 2W9I (22) .
Virtual screening with Vina
Virtual screening of 1364 compounds that comprise the NCI Diversity Set II was initially performed with AutoDock Vina in the presence of acetylcholine molecules at both the A-and P-sites, in an effort to identify compounds that bound adjacent to the P-site. From consensus scoring using Vina binding energies, X-Score and CSCORE followed by Lipinski's-rule filtering, sixteen compounds with the highest scores were identified. These compounds were then docked to the human apo-AChE (with no acetylcholine bound to either the A-or Psites) to determine if P-site docking was maintained. Most of the compounds shifted to bind predominantly at the P-site, while some shifted sufficiently to span both the A-and P-sites.
All 16 compounds were obtained from the NCI for testing. Three compounds were insoluble in the assay conditions, and eleven others were inactive (<10% inhibition at 10 lM). Two compounds shown in Figure 5 showed inhibition and were tested in the edrophonium competition assay to assess the extent to which they block the A-site. The affinity of both the compounds in the ternary complex with edrophonium and AChE decreased by a factor of >10 relative to their affinity in their respective binary complexes (Figure 5 ). This result indicated that the compounds overlapped strongly with edrophonium bound at the A-site, in contrast to the binding poses predicted by Vina. As the goal of this screening strategy was to identify inhibitors that did not overlap with the A-site, these compounds were not considered further.
A second round of virtual screening with Vina was also performed with acetylcholine bound only at the A-site, in an attempt to identify compounds that bound specifically at the P-site. Six compounds were predicted to bind at the P-site and were obtained for experimental assay. All six were poorly soluble and were not considered further.
Virtual screening with AUTODOCK 4.2
The docking-based virtual screening of NCI Diversity Set II was repeated using AUTODOCK 4.2, again using apo-AChE and AChE with acetylcholine in either the A-site alone or in both the A-and Psites. This protocol was developed to indicate which compound bound preferentially at the A-site, P-site, or outside either site. Twenty docking poses were generated and clustered, and compounds with predicted binding affinities better than )7.0 kcal ⁄ mol in each of the three docking runs were selected for further analysis and visual inspection. Thirty-eight compounds met these criteria, and sixteen were obtained from the NCI for experimental assay. Of these, four were insoluble and the inhibition from ten others was too low to be of interest (<20% inhibition at 50 lM compound). Two compounds gave greater inhibition of AChE, and one (NSC_358311) had sufficient solubility for analysis with the inhibitor competition assay ( Figure 6 ). Although the affinity of NSC_358311 for AChE was low (K 2 = $100 lM), this assay indicated little overlap with the A-site, as NSC_358311 affinity in the ternary complex with edrophonium and AChE decreased by a factor of about 2 relative to its affinity in the binary complex with AChE ( Figure 6A ). However, no ternary complex involving NSC_358311, thioflavin T, and AChE could be detected (1 ⁄ K 12 = 0), which shows that NSC_358311 binds only at the P-site. This is consistent with the docking result in Figure 7 , which shows complete overlap with the P-site acetylcholine. This predicted binding mode would also allow a ternary complex with NSC_358311 bound at the P-site and acetylcholine at the A-site. Figure 7 also shows that NSC_358311 docks with the same binding mode both to apo-AChE (panel A) and AChE with modeled acetylcholine occupying the A-site (panel B). In this docked conformation, NSC_358311 has 65% volume overlap with the P-site (as defined previously) and zero overlap with the A-site.
Conclusion
Virtual screening of compounds with specificity for the AChE P-site with AutoDock Vina and AUTODOCK 4.2 was tested with compounds whose specificity for the P-site was known from X-ray crystallogra- Figure 7 : NSC_358311 (colored by element) docked to A) apo-AChE, B) AChE with acetylcholine modeled at the A-site. Acetylcholine molecules from crystal structure 2HA4 are superimposed at the P-site (pink) and A-site (green).
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phy. The Vina and AUTODOCK 4.2 docking programs were then used for virtual screening of compounds from the NCI Diversity database, and they identified two different sets of candidates with potential P-site specificity. However, testing of two candidates predicted by Vina with an experimental inhibitor competition assay did not support this specificity. Virtual screening with AUTODOCK 4.2 identified NSC_358311, which the experimental binding competition assay showed to bind specifically to the P-site of AChE, while allowing a ligand to bind simultaneously at the A-site. This molecule may provide a lead for additional virtual screening, and as a good starting point for synthetic modifications that limit access to the A-site in a way that still allows entry of acetylcholine but limits the entrance of the larger OPs.
